Arcus Biosciences (RCUS) Non-Current Assets (2017 - 2026)

Arcus Biosciences' Non-Current Assets history runs 10 years deep, the most recent figure standing at $153.0 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 9.47% year-over-year to $153.0 million; the TTM figure through Mar 2026 stood at $531.0 million (down 18.81% YoY), while the FY2025 annual figure was $132.0 million, down 1.49% from the prior year.
• Non-Current Assets for Q1 2026 stood at $153.0 million, up from $132.0 million in the prior quarter.
• The five-year high for Non-Current Assets was $309.0 million in Q3 2023, with the low at $117.0 million in Q3 2025.
• The 5-year median for Non-Current Assets is $233.0 million (2022), against an average of $207.1 million.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets soared 199.41% in 2022, then plunged 49.24% in 2024.
• Arcus Biosciences' Non-Current Assets stood at $233.0 million in 2022, then climbed by 13.3% to $264.0 million in 2023, then slumped by 49.24% to $134.0 million in 2024, then dropped by 1.49% to $132.0 million in 2025, then grew by 15.91% to $153.0 million in 2026.
• Business Quant data shows RCUS's Non-Current Assets at $153.0 million in Q1 2026, $132.0 million in Q4 2025, and $117.0 million in Q3 2025.